共 38 条
Augmenting Cognitive Function in the Elderly with Mild Cognitive Impairment Using Probiotic Lacticaseibacillus rhamnosus CBT-LR5: A 12-Week Randomized, Double-Blind, Parallel-Group Non-Comparative Study
被引:0
|作者:
Jung, Su-Jin
[1
,2
]
Cho, Kyohee
[3
]
Jung, Eun-Soo
[1
]
Son, Dooheon
[3
]
Byun, Jong-Seon
[3
]
Kim, Song-In
[3
]
Chae, Soo-Wan
[1
,2
]
Yang, Jong-Chul
[1
,2
,4
]
Lee, Seung-Ok
[1
,2
,5
,6
]
Lim, Sanghyun
[3
]
机构:
[1] Jeonbuk Natl Univ Hosp, Clin Trial Ctr Funct Foods, Jeonju 54907, South Korea
[2] Jeonbuk Natl Univ Hosp, Biomed Res Inst, Clin Trial Ctr K FOOD Microbiome, Jeonju 54907, South Korea
[3] Cell Biotech Co Ltd, R&D Ctr, Gimpo Si 10003, South Korea
[4] Jeonbuk Natl Univ, Med Sch, Dept Psychiat, Jeonju 54896, South Korea
[5] Jeonbuk Natl Univ Hosp, Dept Gastroenterol & Hepatol, Jeonju 54896, South Korea
[6] Jeonbuk Natl Univ, Med Sch, Dept Internal Med, Jeonju 54896, South Korea
来源:
关键词:
mild cognitive impairment (MCI);
<italic>Lacticaseibacillus rhamnosus</italic> CBT-LR5;
skim milk;
probiotics;
cognitive function;
clinical trial;
GUT-BRAIN AXIS;
BIOACTIVE PEPTIDES;
FERMENTED MILK;
MICROBIOTA;
MEMORY;
EDUCATION;
DEMENTIA;
D O I:
10.3390/nu17040691
中图分类号:
R15 [营养卫生、食品卫生];
TS201 [基础科学];
学科分类号:
100403 ;
摘要:
Background: Probiotics have been shown to enhance cognitive function in individuals with mild cognitive impairment (MCI), but their efficacy varies, depending on the strain and dosage. Objectives: Clinical investigations are crucial to confirm their safety, efficacy, and mechanism of action. This study was designed to assess the effective dosage, safety, and efficacy of MH-Pro, a test product containing Lacticaseibacillus rhamnosus CBT-LR5 (LR5) and skim milk (non-fat dry milk), in improving cognitive function and related physiological changes in older adults suspected of MCI over 12 weeks. Methods: In total, 20 participants (mean age: 68.9 years) were randomly assigned in a 1:1 ratio to either a low-dose group (1 x 1010 CFU LR5 with 1622 mg) or a high-dose group (1 x 1010 CFU LR5 with 4055 mg skim milk) in a double-blind, parallel-group clinical trial. Results: After 12 weeks, the low-dose group showed significant improvements in the MOCA-K subdomains, specifically in naming (p = 0.01) and delayed recall (p = 0.003). Additionally, levels of amyloid-beta 1 40/42 in the blood significantly decreased (p = 0.03) following supplementation in the low-dose group. The high-dose group exhibited significant improvement in orientation (p = 0.05). Moreover, overall cognitive enhancement was observed in the low-dose group (p = 0.003), while the high-dose group showed a trend toward improvement (p = 0.06). Fecal analysis revealed significant changes in bacterial composition, with an increase in Lacticaseibacillus after 12 weeks of MH-Pro consumption. Together, these findings provide foundational evidence suggesting that MH-Pro supplementation may serve as a potential intervention for enhancing cognitive function through gut-brain axis pathways in the elderly population. However, given the small sample size and the predominance of female participants, the impact of the outcome may be limited. Further large-scale studies are necessary to validate these preliminary results. Conclusions: This study provides foundational evidence to recognize the use of LR5 and skim milk to prepare a probiotic supplement that enhances cognitive function in the aging population.
引用
收藏
页数:19
相关论文